PAC326: A Randomized, Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythermia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study will find out if an experimental drug called pacritinib works better than best available therapies.
Primary Sponsor: CTI BioPharma Corp
Prinicipal Investigator: Imad A.Tabbara, M.D.
Contact Phone: (202) 741-2981
Are you interested in more information on this clinical trial?